SWM
ITCI

SeaCrest Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

SeaCrest Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,900
Closed -$251K – 708
2025
Q1 		$251K Buy
+1,900
New +$237K 0.03% 548
2023
Q3 		– Sell
-9,703
Closed -$614K – 658
2023
Q2 		$614K Buy
+9,703
New +$605K 0.08% 271
2022
Q4 		– Sell
-9,090
Closed -$423K – 669
2022
Q3 		$423K Sell
9,090
-1,249
-12% -$65.2K 0.06% 342
2022
Q2 		$590K Sell
10,339
-77
-0.7% -$4.37K 0.07% 279
2022
Q1 		$637K Sell
10,416
-258
-2% -$13.4K 0.07% 290
2021
Q4 		$559K Buy
+10,674
New +$448K 0.06% 321
2020
Q4 		– Sell
-7,795
Closed -$200K – 658
2020
Q3 		$200K Buy
+7,795
New +$178K 0.03% 518
2019
Q2 		– Sell
-3,673
Closed -$45K – 1911
2019
Q1 		$45K Sell
3,673
-6,713
-65% -$85.8K 0.01% 983
2018
Q4 		$118K Sell
10,386
-16,100
-61% -$260K 0.02% 602
2018
Q3 		$575K Sell
26,486
-2,364
-8% -$49.4K 0.1% 224
2018
Q2 		$510K Sell
28,850
-388
-1% -$7.88K 0.09% 241
2018
Q1 		$615K Buy
29,238
+222
+0.8% +$4.32K 0.11% 190
2017
Q4 		$420K Buy
+29,016
New +$448K 0.08% 283

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

SeaCrest Wealth Management's ITCI Position: Q2 2025 in Review

SeaCrest Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,900 shares — an estimated $251K sold.

SeaCrest Wealth Management first reported a position in ITCI in Q4 2017 and held it in 13 quarters. The position peaked at $637K in Q1 2022. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • SeaCrest Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,900 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $251K.
  • SeaCrest Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and held it in 13 quarters.
  • SeaCrest Wealth Management's Intra-Cellular Therapies Inc. position peaked at $637K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on SeaCrest Wealth Management's 13F filing for Q2 2025, filed 11 Jul 2025.